Please assess the completion status of the following clinical trial:

Trial Title: EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible.~* Patient must be \> 18 years of age.~* Patient and treating interventional cardiologist agree for randomization.~* Patient will be informed of the randomization process and will sign an informed consent.~* Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.~Exclusion Criteria:~CLINICAL:~* Patients with recent (\< 72 hrs) Q-wave (ST elevation) acute myocardial infarction.~* History of LV ejection fraction ≤ 30%.~* Unstable clinical condition.~* Any complication compromising ambulation~* Concurrent participation in other investigational study requiring prolonged hospitalization~* Required prolonged hospitalization~* In-cath lab transient vessel closure~* Resuscitation per PCI~* Hemodynamic collapse during PCI~* Severe entry site complication upon investigator decision~* Social isolation~* Serious cognitive disorders~* Femoral sheath (artery)~* Persisting chest pain~* No ASA prior PCI~* Allergy to ASA or thienopyridines precluding treatment for 30 days~* Any significant blood dyscrasia~* PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis)~* International Normalised Ratio (INR) \> 2.0~* Contraindication to Reopro administration~ANGIOGRAPHIC~* Residual dissection of grade ≥ B of NHBLI classification.~* Compromised or sub-occluded branch with diameter ≥ 1 mm.~* Timi \< 3 post-stenting~* Thrombus post-PCI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).